Isosorbide dinitrate/hydralazine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Isosorbide dinitrate/hydralazine
Combination of
Isosorbide dinitrate Vasodilator
Hydralazine Antihypertensive
Clinical data
Legal status
?
Identifiers
CAS number 682335-44-0 YesY
ATC code ?
PubChem CID 9843669
ChemSpider 8019384 YesY
 YesY (what is this?)  (verify)

Isosorbide dinitrate/hydralazine is a fixed dose combination drug treatment specifically indicated for African Americans with congestive heart failure. It is a combination of hydralazine (an antihypertensive) and isosorbide dinitrate (a vasodilator). It is the first race-based prescription drug in the United States.[1]:7

The combination preparation is marketed in the United States under the trade name BiDil by Arbor Pharmaceuticals, Inc. which purchased the rights to market the drug in December 2011 from NitroMed.

Background[edit]

From 1980 to 1985 Dr. Jay Cohn of the University of Minnesota led a clinical trial in collaboration with the US Veterans Administration called the Vasodilator-Heart Failure Trial (V-HeFT I) that tested whether the combination of Isosorbide dinitrate and hydralazine increased survival in patients with heart failure; the results were promising and the study was followed by V-HeFT II, which tested the combination against enalapril.[2] In the meantime, Cohn applied for a patent on the combination treatment, which issued in 1989 as US Patent 4868179.[3] Cohn licensed the patent to a company called Medco, and Medco spent the early 1990s preparing a New Drug Application (NDA) to get the FDA to approve BiDil on the basis of the V-HeFT trials. However, the trials were not designed to support an NDA, and in 1997 the FDA rejected the application because it did not have enough statistical power to show whether the combination really worked.[2]

Cohn re-analyzed the data and found a signal that the drug combination appeared to work better in self-identified African-Americans in the V-HeFT trial, and published a paper on that work, and filed a new patent on the use of BiDil in "black" patients.[2][4][5] It had already been known that African-Americans with congestive heart failure (CHF) respond less effectively to conventional CHF treatments (particularly ACE inhibitors) than caucasians.[6]

The new patent and the old patent were licensed to a company called NitroMed, which ran a clinical called the African-American Heart Failure Trial (A-HeFT), the results of which were published in 2004 in the New England Journal of Medicine.[7] The clinical trial was stopped early because the drug worked so well; it reduced mortality by 43%, reduced hospitalizations by 39%, and improved quality of life markers in African-American patients with CHF.[7]

On the basis of A-HeFT, the FDA approved BiDil in June 2005.[2][8][9] In 2006, the Heart Failure Society of America included the use of the fixed dose combination of isosorbide dinitrate/hydralazine as the standard of care in the treatment of heart failure in blacks.[10]:e44

Though BiDil must still be taken three times daily, as must the component pills in separate ISDN-H treatment, the reduction in pill burden has been suggested to improve compliance, and thus a better medical outcome.[11]

Controversy[edit]

The new drug application claiming treatment of a single, self-identified racial group raised a storm of controversy, with some hailing a breakthrough for African-Americans, and others decrying a new form of scientific racism.[2][12][13][14][15][16] Additionally, some disagreed with the design of the A-HeFT trial because the trial failed to include any non-African American test subjects.[17]

See also[edit]

References[edit]

  1. ^ Whitmarsh, Ian; Jones, David S., eds. (2010). What's the Use of Race?: Modern Governance and the Biology of Difference. Cambridge (MA): MIT Press. ISBN 978-0-262-51424-8. Lay summary (28 April 2013). 
  2. ^ a b c d e Jonathan Kahn. BiDil and Racialized Medicine. Chapter 7 in Race and the Genetic Revolution: Science, Myth, and Culture, Eds Sheldon Krimsky and Kathleen Sloan. Columbia University Press. Isbn: 978-0-231-52769-9
  3. ^ US4868179
  4. ^ Carson P, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group J Card Fail. 1999 Sep;5(3):178-87.
  5. ^ US Patent 6465463
  6. ^ Exner DV, Dries DL, Domanski MJ, Cohn JN (2001). "Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction". N Engl J Med 344 (18): 1351–7. doi:10.1056/NEJM200105033441802. PMID 11333991. 
  7. ^ a b Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN (2004). "Combination of isosorbide dinitrate and hydralazine in blacks with heart failure". N Engl J Med 351 (20): 2049–57. doi:10.1056/NEJMoa042934. PMID 15533851. 
  8. ^ FDA approval process page
  9. ^ FDA approval press release
  10. ^ Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline J Card Fail. 2006 Feb;12(1):e1-e122.
  11. ^ Steve Stiles (13 December 2006), BiDil, regulatory milestone but a tough sell for insurers and patients, charts uncertain course 
  12. ^ WNYC Radiolab audio story about racial issues surrounding Bidil
  13. ^ Editors, Scientific American. July 31, 2007 Race-Based Medicine: A Recipe for Controversy
  14. ^ Scientific American article criticizing approval of Bidil
  15. ^ Scientific American article response by manufacturer to previous article's criticism
  16. ^ Response for FDA's Robert Temple to Scientific American article
  17. ^ Puckrein, G. (2006). BiDil: From Another Vantage Point. Health Affairs . Retrieved October 1, 2013, from http://content.healthaffairs.org/content/25/5/w368.long

External links[edit]